Interventional radiology

Zomedica to Focus on TRUFORMA™ Commercialization

Retrieved on: 
Thursday, January 23, 2020
Biopsy, Interventional radiology

The TRUFORMA platform uses Bulk Acoustic Wave (BAW) technology to provide a non-optical and fluorescence-free detection system for use at the point-of-care.

Key Points: 
  • The TRUFORMA platform uses Bulk Acoustic Wave (BAW) technology to provide a non-optical and fluorescence-free detection system for use at the point-of-care.
  • Zomedica believes that the TRUFORMA instrument is the first to use BAW technology in disorder and disease-state diagnostics.
  • This strategic change will focus the entire Zomedica team on the completion of the development and the beginning of commercialization of TRUFORMA.
  • Zomedica will also seek partners to continue the development and commercialization of its therapeutic assets and reference lab liquid biopsy platform.

Argon Medical Announces the Commercial Launch of Two Inferior Vena Cava Filter Retrieval Kits

Retrieved on: 
Wednesday, January 22, 2020
Medicine, Medical specialties, Interventional radiology, Clinical medicine, Inferior vena cava filter, Percutaneous, Vascular surgery, Inferior vena cava, Radiology, IVC, International Video Corporation, Interventional oncology

FRISCO, Texas, Jan. 22, 2020 /PRNewswire/ --Argon Medical Devices, Inc. announced today the commercial launch of Single-Loop and Triple-Loop Retrieval Kits for sale in the U.S.

Key Points: 
  • FRISCO, Texas, Jan. 22, 2020 /PRNewswire/ --Argon Medical Devices, Inc. announced today the commercial launch of Single-Loop and Triple-Loop Retrieval Kits for sale in the U.S.
  • The Single-Loop and Triple-Loop Retrieval Kits are intended for percutaneous removal of retrievable inferior vena cava (IVC) filters that are no longer medically required, via a jugular approach.
  • "We are excited to improve the IVC filter retrieval options available to our customers with the introduction of these new products," said George A. Leondis, President and CEO of Argon Medical Devices, Inc. "Our Single-Loop and Triple-Loop Retrieval Kits are the only two kits cleared by the FDA for removing any retrievable IVC filter from a jugular approach.
  • Argon Medical Devices, Inc., based inFrisco, TX, is a global manufacturer of specialty medical devices used in interventional procedures.Argon offers a broad line of disposable medical devices for Interventional Radiology, Interventional Oncology and Vascular Surgery.

Ra Medical Systems Receives FDA IDE Approval to Begin Pivotal Atherectomy Clinical Study

Retrieved on: 
Tuesday, January 21, 2020
Public relations, Investor relations, General Health, Health, FDA, Medical devices, Communications, Clinical trials, Other Health, Medical specialties, Interventional radiology, Medicine, Atherectomy, Health, Peripheral artery disease, Dabra, Gwalior, Excimer laser, Food and Drug Administration, DABRA, Ra Medical Systems

In May 2017, DABRA received FDA 510(k) clearance for use in ablating a channel in occlusive peripheral vascular disease (PAD).

Key Points: 
  • In May 2017, DABRA received FDA 510(k) clearance for use in ablating a channel in occlusive peripheral vascular disease (PAD).
  • We are delighted the FDA has granted this IDE allowing us to pursue an atherectomy indication for DABRA and anticipate enrolling the first patient into the trial in the next few months, said Andrew Jackson, Ra Medical Systems CFO and Interim CEO.
  • Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases.
  • Forward-looking statements in this press release include, but are not limited to, statements regarding the timing and potential outcome of the DABRA atherectomy clinical study.

Zomedica Successfully Completes Development and Manufacturing Milestones for its Cancer Liquid Biopsy Platform

Retrieved on: 
Monday, January 20, 2020
Medicine, Clinical medicine, Medical specialties, Biopsy, Sarcoma, Cancer in cats, Cancer in dogs, Interventional radiology, Liquid biopsy, Oncology, Hemangiosarcoma, Veterinarian

ANN ARBOR, Mich., Jan. 20, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced it has successfully completed the development and manufacturing milestones for its reference lab cancer liquid biopsy platform.

Key Points: 
  • ANN ARBOR, Mich., Jan. 20, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced it has successfully completed the development and manufacturing milestones for its reference lab cancer liquid biopsy platform.
  • Zomedica is developing assays for the detection of hemangiosarcoma, osteosarcoma, and lymphoma, for use with its liquid biopsy platform.
  • Under the terms of the restated agreement, Zomedica continues to have veterinary oncology care exclusive global rights to develop and market Celsees liquid biopsy platform for use by veterinarians as a cancer diagnostic.
  • Zomedica initially intends to develop and market the platform and its non-invasive diagnostic assays or blood test that helps veterinarians diagnose cancer in canines.

AngioDynamics Launches PATHFINDER I Registry to Evaluate Performance and Clinical Outcomes of the AURYON™ Atherectomy System

Retrieved on: 
Thursday, January 16, 2020
Oncology, Medical devices, Health, Surgery, Other Health, Cardiology, Medicine, Medical specialties, Interventional radiology, Clinical medicine, Atherectomy, Vascular surgery, Angiography

The AURYON Atherectomy System, previously known as the Eximo B-Laser, is a proprietary 355nm wavelength laser-technology platform that was acquired by AngioDynamics in October 2019.

Key Points: 
  • The AURYON Atherectomy System, previously known as the Eximo B-Laser, is a proprietary 355nm wavelength laser-technology platform that was acquired by AngioDynamics in October 2019.
  • AngioDynamics PATHFINDER I Registry is a prospective, non-randomized, single arm, multicenter observational study that will evaluate the performance of the AURYON Atherectomy System during procedures and measure clinical outcomes, both intermediate and long-term.
  • As previously communicated, the commercial release of the AURYON Atherectomy System in the United States will occur in the second half of AngioDynamics current fiscal year.
  • For more information about the AURYON Atherectomy System, visit Auryon-PAD.com for more information.

Global Vascular Embolization Devices Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Boston Scientific Corp. | Technavio

Retrieved on: 
Thursday, January 16, 2020
Medical devices, Health, Interventional radiology, Embolization, Surgery

Furthermore, innovation in embolization products and procedures will positively impact the vascular embolization devices market during the forecast period.

Key Points: 
  • Furthermore, innovation in embolization products and procedures will positively impact the vascular embolization devices market during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20200116005253/en/
    Technavio has announced its latest market research report titled global vascular embolization devices market 2020-2024.
  • Vascular Embolization Devices Market Product Outlook (Revenue, USD Million, 2020-2024)
    Non-coiling devices segment is expected to grow faster than the overall market during 2020-2024.
  • Vascular Embolization Devices Market Regional Outlook (Revenue, USD Million, 2020-2024)
    North America will be the largest geographical segment of the global vascular embolization devices market throughout 2020-2024.

2019 Study on the Advances and Emerging Technologies in Interventional Radiology - Technology Roadmap & Growth Opportunity, Intellectual Property Landscape

Retrieved on: 
Wednesday, January 15, 2020
Medical imaging, Radiology, Medicine, Interventional radiology, Health, American College of Radiology, Interventional magnetic resonance imaging

4.2 Growth Opportunities - Patient Centric, Patient Specific, and Cost-effective Imaging Redefining Future of Interventional Radiology

Key Points: 

4.2 Growth Opportunities - Patient Centric, Patient Specific, and Cost-effective Imaging Redefining Future of Interventional Radiology
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Hydromer Enters Into New Commercial Relationship Agreements With Multiple Clients to Kick-off the New Year 2020

Retrieved on: 
Tuesday, January 14, 2020
Medicine, Interventional cardiology, Clinical medicine, Interventional radiology, Medical imaging

A well-established East Asia-based global manufacturer of advanced guidewires made of Stainless Steel and precious metals.

Key Points: 
  • A well-established East Asia-based global manufacturer of advanced guidewires made of Stainless Steel and precious metals.
  • Hydromer coated guidewires will be used in various interventional proceduressuch as peripheral vascular,coronary and neurovascular.
  • Hydromer coatings provide increased torquingability for torturous anatomy, improved push-ability within the vessels and enhance userhandling skills.
  • Hydromer coated wires will be used in many different medical interventional procedures in the growing Asia market.

Scripps La Jolla First in U.S. to Use ZOLL’s FDA-approved Supersaturated Oxygen Therapy on Patients Suffering From Widowmaker Heart Attacks

Retrieved on: 
Tuesday, January 14, 2020
Technology, Medical devices, Hospitals, FDA, Cardiology, Software, Other Health, Biotechnology, Health, Data management, Medicine, Cardiovascular system, Circulatory system, Aging-associated diseases, RTT, Medical emergencies, Angioplasty, Interventional radiology, Myocardial infarction, Widow maker, Transmyocardial revascularization, ZOLL Medical Corporation, Asahi Kasei

ZOLL Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that Scripps Memorial Hospital La Jolla, in San Diego, Calif., treated its first widowmaker heart attack patient with SuperSaturated Oxygen (SSO2) Therapy.

Key Points: 
  • ZOLL Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that Scripps Memorial Hospital La Jolla, in San Diego, Calif., treated its first widowmaker heart attack patient with SuperSaturated Oxygen (SSO2) Therapy.
  • For many patients, even after blood flow is quickly restored with angioplasty and stenting, irreversible damage to the heart muscle may occur.
  • SSO2 Therapy delivers localized superoxygenated blood, with the goal of improving microvascular blood flow and reducing damage to the heart muscle.
  • More than 30% percent of severe heart attack patients develop heart failure,3 and of those, 50% will die within five years.3 SSO2 Therapy has been shown in randomized prospective clinical trials to safely reduce infarct size in widowmaker heart attack patients.

Lucence Presents Data Demonstrating Potential of AmpliMARK™-Powered Sequencing to Detect Genomic Alterations at High Sensitivity in Blood Cancers

Retrieved on: 
Tuesday, January 14, 2020
Biotechnology, Pharmaceutical, Managed care, Oncology, Health, Medical devices, Genetics, Other Health, Medicine, Clinical medicine, Medical specialties, Biopsy, RTT, Interventional radiology, Liquid biopsy, Anatomical pathology, Leukemia, Tumors of the hematopoietic and lymphoid tissues, Cancer, Hematology

Lucences amplicon-based sequencing technology, known as AmpliMARK, can provide high sensitivity mutation detection in blood for multiple solid tumor types.

Key Points: 
  • Lucences amplicon-based sequencing technology, known as AmpliMARK, can provide high sensitivity mutation detection in blood for multiple solid tumor types.
  • Liquid biopsy aims to use blood as a platform for cancer screening, diagnosis, treatment, and monitoring.
  • In the case of hematological malignancies like leukemia, current bone marrow-based tests for detecting and monitoring disease progression offer limited sensitivity and are highly invasive.
  • Lucences findings suggest that a blood-based liquid biopsy test could be a compelling, highly sensitive clinical alternative to these tests.